MoneyWorks4Me

USFDA concludes cGMP inspection at Cipla’s Bangalore facility

27 Jan 2020 Evaluate

United States Food and Drug Administration (USFDA) has concluded a cGMP inspection at Cipla’s API manufacturing facility in Bommasandra, Bangalore from January 20 - 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Peers
Company Name CMP
Sun Pharma. Inds. 1840.00
Dr. Reddys Labs. 1222.50
Cipla 1388.90
Lupin 2061.85
Zydus Lifesciences 1212.00
View more..